HKD77.35
1.59% yesterday
Hong Kong, Jun 27, 10:09 am CET
ISIN
KYG4818G1010
Symbol
1801
Sector
Industry

Innovent Biologics Stock price

HKD77.35
+17.80 29.89% 1M
+41.75 117.28% 6M
+40.75 111.34% YTD
+38.30 98.08% 1Y
+41.85 117.89% 3Y
+19.20 33.02% 5Y
+60.77 366.53% 10Y
+60.77 366.53% 20Y
Hong Kong, Closing price Fri, Jun 27 2025
-1.25 1.59%
ISIN
KYG4818G1010
Symbol
1801
Sector
Industry

Key metrics

Basic
Market capitalization
HKD129.8b
Enterprise Value
HKD124.4b
Net debt
HKD-5.4b
Cash
HKD8.5b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
negative | 320.79
P/S
12.59 | 10.04
EV/Sales
12.07 | 9.63
EV/FCF
negative
P/B
8.83
Financial Health
Equity Ratio
60.72%
Return on Equity
-0.72%
ROCE
-1.49%
ROIC
-2.47%
Debt/Equity
0.22
Financials (TTM | estimate)
Revenue
HKD10.3b | HKD12.9b
EBITDA
HKD178.9m | HKD863.4m
EBIT
HKD-280.5m
Net Income
HKD-103.6m | HKD395.0m
Free Cash Flow
HKD-388.6m
Growth (TTM | estimate)
Revenue
51.82% | 25.37%
EBITDA
121.76% | 111.74%
EBIT
77.45%
Net Income
90.79% | 481.38%
Free Cash Flow
71.23%
Margin (TTM | estimate)
Gross
83.97%
EBITDA
1.74% | 6.68%
EBIT
-2.72%
Net
-1.00% | 3.06%
Free Cash Flow
-3.77%
More
EPS
HKD-0.07
FCF per Share
HKD-0.24
Short interest
-
Employees
5.66k
Rev per Employee
HKD1.82m
Show more

Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Innovent Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Innovent Biologics forecast:

29x Buy
91%
2x Hold
6%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Innovent Biologics forecast:

Buy
91%
Hold
6%
Sell
3%

Financial data from Innovent Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10,312 10,312
52% 52%
100%
- Direct Costs 1,653 1,653
33% 33%
16%
8,659 8,659
56% 56%
84%
- Selling and Administrative Expenses 5,565 5,565
32% 32%
54%
- Research and Development Expense 2,934 2,934
20% 20%
28%
179 179
122% 122%
2%
- Depreciation and Amortization 459 459
9% 9%
4%
EBIT (Operating Income) EBIT -280 -280
77% 77%
-3%
Net Profit -104 -104
91% 91%
-1%

In millions HKD.

Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.

Head office China
Employees 5,659
Website www.innoventbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today